What’s New in the Guidelines

Jan 05, 2022 · This section has been updated to incorporate information on the newly authorized use of bamlanivimab plus etesevimab as treatment or post-exposure prophylaxis (PEP) for children aged <12 years who are at risk of serious COVID-19. The text and Table A also now include information on the Omicron variant and its potential impact

  Guidelines, Bamlanivimab

MAB Order Form

OR bamlanivimab and etesevimab (Eli Lilly) once by IV infusion OR Sotrovimab (GSK) once by IV infusion Ordering Providers Signature: Date: Time: PROVIDER DECLARATION Whether provided in person or virtually, I confirm that this patient or legal representative has recei ved a full

  Bamlanivimab

UPDATE 6-9-21: JHMI Clinical Recommendations for ...

Jun 06, 2021 · UPDATE 6-9-21_PGA . 1 . JHMI Clinical Recommendations for Pharmacologic Treatment of COVID-19 . Updated 6/9/2021 and replaces the version of April 5, 2021